Know Cancer

forgot password

Efficacy of Post-Surgical Stereotactic Radiosurgery for Metastatic Brain Disease: A Randomized Trial

Phase 3
3 Years
Open (Enrolling)
Brain Disease

Thank you

Trial Information

Efficacy of Post-Surgical Stereotactic Radiosurgery for Metastatic Brain Disease: A Randomized Trial

After surgery to remove brain metastasis, patients are usually given whole brain
radiotherapy because of the risk of the tumor regrowing in that area or in other places in
the brain. It is given in 10-14 daily sessions over 2-3 weeks. Because of the potential
side effects of whole brain radiotherapy, stereotactic radiosurgery to the area of the brain
with metastasis or observation is also used.

This study will be using stereotactic radiosurgery or observation instead of whole brain

Stereotactic radiosurgery is a highly focused, 1 day outpatient radiation procedure.

Observation is checking the brain through repeat magnetic resonance imagine (MRI) scans, but
performing no treatment.

Study Groups:

If you agree to take part in this study, you will be randomly assigned (as in the flip of a
coin) to 1 of 2 groups.

- Group 1 will receive stereotactic radiosurgery to the area of the brain that had the
brain metastasis removed.

- Group 2 will be observed with routine MRI scans only.

You will have an equal chance of being assigned to either group.

Stereotactic Radiosurgery:

Stereotactic radiosurgery will be offered for treatment of any tumor that was not removed by
surgery whether or not you are randomized to treatment of the surgical bed or not.

If you are assigned to receive stereotactic radiosurgery, your neurosurgeon and radiation
oncologist will discuss the procedure with you in detail. You will also sign a separate
consent form, which will include the potential risks.

Stereotactic radiosurgery requires the placement of a stereotactic head frame, which is a
ring attached to the head with 4 small pins. The frame placement is done with local
anesthetic (numbing medicine) by the neurosurgeon on the day of the procedure and will
remain in place until the end of the stereotactic radiosurgery later in the day. The
stereotactic frame will help the doctor to target the radiotherapy to the area of the
surgery that was found by an MRI scan. The surgical area and up to 2 other lesions will be

Study Visits:

You will have standard MRI scans of the brain after surgery, at 5-8 weeks after surgery,
every 6-9 weeks for a year, and then every 3-4 months after that. At these times, the area
of surgery and any other brain tumors that were treated will be evaluated for regrowth or
side effects from the treatment. The doctors will also decide whether there are any new
lesions that require treatment.

Length of Study:

You will be considered to be off study if the tumor has returned to the surgery site or if
whole brain radiotherapy is used.

This is an investigational study. Stereotactic radiosurgery is FDA approved and
commercially available. The comparison of stereotactic radiosurgery to observation is

Up to 132 patients will take part in this study. All will be enrolled at MD Anderson.

Inclusion Criteria:

1. Patients must be older than 3 years of age (radiosurgical frames cannot be placed on
children younger than age 3).

2. Patients must have 3 or fewer newly diagnosed metastatic lesions in the brain with a
complete resection of at least one lesion as determined the study neuroradiologist.

3. The resection cavity must have a maximum diameter of less than or equal to 4cm. This
criteria will be determined by the study radiologist.

4. Additional unresected brain metastases (up to 2) must have a maximum diameter of less
than or equal to 3 cm.

5. Patients must be considered candidates for SRS within 30 days of surgical resection.

6. Patients must have a Karnofsky Performance Scores (KPS) of at least 70 at the first
post operative visit. Patients under 18 years of age must have a Lansky Performance
Score of of at least 70.

7. Patients must be able to undergo an MRI scan.

8. Patients must agree to randomization as documented by signing the Institutional
Review Board (IRB) approved consent form.

Exclusion Criteria:

1. Patients who have received prior radiation therapy to the brain for any reason.

2. There is radiographic evidence of leptomeningeal disease prior to study entry.

3. The primary tumor is small-cell lung cancer, lymphoma, leukemia, or multiple myeloma.

4. For females, if they are pregnant or breast-feeding (The exclusion is made because
gadolinium may be teratogenic in pregnancy).

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Time to Local Recurrence (TTLR)

Outcome Time Frame:

Differences in TTLR will be monitored at 3 timepoints and will take place: 1) after a total of 39 events occur; 2) after 77 events occur; and 3) after at least 115 events occur.

Safety Issue:


Principal Investigator

Anita Mahajan, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

UT MD Anderson Cancer Center


United States: Institutional Review Board

Study ID:




Start Date:

August 2009

Completion Date:

Related Keywords:

  • Brain Disease
  • Brain tumors
  • Metastatic brain disease
  • Post-surgical
  • Stereotactic radiosurgery
  • SRS
  • Whole brain radiotherapy
  • MRI
  • Magnetic Resonance Imaging
  • Outpatient radiation procedure
  • Brain Diseases



UT MD Anderson Cancer CenterHouston, Texas  77030